Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, on Cardio-Ankle Vascular Index in Type 2 Diabetic Patients

Original Articles

Yoh Miyashita, Kei Endo, Atsuhito Saiki, Noriko Ban, Takashi Yamaguchi, Hidetoshi Kawana, Daiji Nagayama, Masahiro Ohira, Tomokazu Oyama, Kohji Shirai

Author information

Yoh Miyashita
Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University
Kei Endo
Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University
Atsuhito Saiki
Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University
Noriko Ban
Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University
Takashi Yamaguchi
Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University
Hidetoshi Kawana
Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University
Daiji Nagayama
Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University
Masahiro Ohira
Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University
Tomokazu Oyama
Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University
Kohji Shirai
Departments of Internal Medicine, Sakura Medical Center, School of Medicine, Toho University

Keywords: Pitavastatin, Oxidative stress, 8-hydroxy-2'-deoxyguanosine, Malondialdehyde-LDL, Cardio-ankle vascular index

JOURNAL OPEN ACCESS

2009 Volume 16 Issue 5 Pages 539-545

DOI https://doi.org/10.5551/jat.281

View "Advance Publication" version (November 10, 2009).

Details

Abstract

Aim: A novel device has been developed for measuring the cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness. In this study, we evaluated the effect of pitavastatin on CAVI in type 2 diabetic patients.
Methods: Forty-five type 2 diabetes mellitus patients with low-density lipoprotein cholesterolemia were enrolled and treated with pitavastatin 2 mg/day for 12 months. Before and after pitavastatin administration, HbA1c, serum lipids, serum malondialdehyde-LDL (MDA-LDL), urinary 8-hydroxy- 2'-deoxyguanosine (8-OHdG) and CAVI were measured.
Results: After pitavastatin treatment for 12 months, significant decreases in 8-OHdG, MDA-LDL and CAVI were observed. ΔCAVI significantly correlated with ΔMDA-LDL.
Conclusions: In type 2 diabetic patients, pitavastatin may have an oxidative stress-reducing effect, especially in a state of enhanced oxidative stress, and CAVI may be useful as a routine test for the diagnosis and therapeutic monitoring of atherosclerosis.

Corresponding author

Register with J-STAGE for free!